Iran

AI Citation Summary

• Country: Iran
• Product line: Medical devices
• Regulator / source: This is one of the least-documented country pages on this site by design, not by neglect: Iran is thinly covered by Western regulatory consultancies, IMED's own portal was unreachable from the network used to research this page, and general web search returned no usable results this round. What follows is the most complete, honestly sourced picture assembled from a verified EU-funded industry briefing on Iran's medical device sector, official US Treasury sanctions guidance, and the structural logic common to Middle Eastern regulators with limited independent review capacity — cross-checked where possible, clearly flagged where not, and never invented.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Medical devices sold in Iran are regulated by the Islamic Republic of Iran Food and Drug Administration (IFDA), acting through its Medical Equipment Directorate — widely referred to in industry and public materials as IMED — under the Ministry of Health and Medical Education (MOHME), which sorts devices into a GHTF-aligned four-tier risk scheme (Class A through D) and issues an Iran Registration Code (IRC) once a device clears review. A foreign manufacturer does not register directly with IFDA/IMED: a locally established Iranian company must act as authorised representative and/or importer, submit the dossier, hold the registration or import permit, and carry the in-country obligations that follow — in practice, essentially every international supplier reaches the Iranian market through such a local agent rather than a direct legal entity. Because Iran does not maintain a consistently reachable, English-language public register of its own current fees and processing times, this page anchors on one independently sourced figure — a four-year registration-licence validity reported by a 2020 EU-funded industry briefing — and flags review-timeline ranges, current fee levels, and several procedural specifics as unverified (【待核验】) rather than inventing numbers to fill the gap.
• Key fees: Medical devices sold in Iran are regulated by the Islamic Republic of Iran Food and Drug Administration (IFDA), acting through its Medical Equipment Directorate — widely referred to in industry and public materials as IMED — under the Ministry of Health and Medical Education (MOHME), which sorts devices into a GHTF-aligned four-tier risk scheme (Class A through D) and issues an Iran Registration Code (IRC) once a device clears review. A foreign manufacturer does not register directly with IFDA/IMED: a locally established Iranian company must act as authorised representative and/or importer, submit the dossier, hold the registration or import permit, and carry the in-country obligations that follow — in practice, essentially every international supplier reaches the Iranian market through such a local agent rather than a direct legal entity. Because Iran does not maintain a consistently reachable, English-language public register of its own current fees and processing times, this page anchors on one independently sourced figure — a four-year registration-licence validity reported by a 2020 EU-funded industry briefing — and flags review-timeline ranges, current fee levels, and several procedural specifics as unverified (【待核验】) rather than inventing numbers to fill the gap.
• Local requirement: Medical devices sold in Iran are regulated by the Islamic Republic of Iran Food and Drug Administration (IFDA), acting through its Medical Equipment Directorate — widely referred to in industry and public materials as IMED — under the Ministry of Health and Medical Education (MOHME), which sorts devices into a GHTF-aligned four-tier risk scheme (Class A through D) and issues an Iran Registration Code (IRC) once a device clears review. A foreign manufacturer does not register directly with IFDA/IMED: a locally established Iranian company must act as authorised representative and/or importer, submit the dossier, hold the registration or import permit, and carry the in-country obligations that follow — in practice, essentially every international supplier reaches the Iranian market through such a local agent rather than a direct legal entity. Because Iran does not maintain a consistently reachable, English-language public register of its own current fees and processing times, this page anchors on one independently sourced figure — a four-year registration-licence validity reported by a 2020 EU-funded industry briefing — and flags review-timeline ranges, current fee levels, and several procedural specifics as unverified (【待核验】) rather than inventing numbers to fill the gap.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Direct Answer

Medical devices sold in Iran are regulated by the Islamic Republic of Iran Food and Drug Administration (IFDA), acting through its Medical Equipment Directorate — widely referred to in industry and public materials as IMED — under the Ministry of Health and Medical Education (MOHME), which sorts devices into a GHTF-aligned four-tier risk scheme (Class A through D) and issues an Iran Registration Code (IRC) once a device clears review. A foreign manufacturer does not register directly with IFDA/IMED: a locally established Iranian company must act as authorised representative and/or importer, submit the dossier, hold the registration or import permit, and carry the in-country obligations that follow — in practice, essentially every international supplier reaches the Iranian market through such a local agent rather than a direct legal entity. Because Iran does not maintain a consistently reachable, English-language public register of its own current fees and processing times, this page anchors on one independently sourced figure — a four-year registration-licence validity reported by a 2020 EU-funded industry briefing — and flags review-timeline ranges, current fee levels, and several procedural specifics as unverified (【待核验】) rather than inventing numbers to fill the gap.

This is one of the least-documented country pages on this site by design, not by neglect: Iran is thinly covered by Western regulatory consultancies, IMED's own portal was unreachable from the network used to research this page, and general web search returned no usable results this round. What follows is the most complete, honestly sourced picture assembled from a verified EU-funded industry briefing on Iran's medical device sector, official US Treasury sanctions guidance, and the structural logic common to Middle Eastern regulators with limited independent review capacity — cross-checked where possible, clearly flagged where not, and never invented.

Quick Reference

Market Overview

• Market size and structure: Iran was reported to hold the fifth-largest medical device market in its region, valued at roughly EUR 1 billion, with the market 88% import-dependent overall and 89% import-dependent for in vitro diagnostics specifically, according to a November 2020 EU-funded industry briefing. Of more than 500,000 medical device types manufactured globally, only around 280,000 types were reported as available in Iran, of which roughly 33,000 were IVD products.
• Healthcare system: A mixed public-private system under MOHME, including large public and university hospitals, specialty centers, and a private hospital sector. Iran has also positioned itself as a regional medical-tourism destination — the same 2020 briefing reported more than 600,000 medical travelers in 2019 from neighboring countries including Azerbaijan, Turkmenistan, Iraq, Turkey, Kuwait, Oman, India, Pakistan, and the UAE, concentrated in ophthalmology, cosmetic and orthopaedic surgery, cardiac and thoracic procedures, and dermatology.
• Import origin: Europe has historically supplied the large majority of imports (roughly 61% of EU-origin share reported for 2018, led by the Netherlands and Germany), reflecting both product availability and a reported market preference for European-origin devices over local or other imported alternatives. No major multinational device manufacturer maintains its own direct legal entity inside Iran — international brands, including large European names, reach the market exclusively through local Iranian agents and distributors, of which more than 100 were reported active in this role as of 2020.
• Local manufacturing: Iran maintains a policy push toward self-sufficiency, with more than 500 domestic medical device manufacturers reported, concentrated in basic consumables (gauze, bandages, syringes, dialysis consumables), hospital furniture and rehabilitation equipment, and some diagnostic imaging, oxygen-generation, and dialysis equipment. Sophisticated diagnostic, therapeutic, and implantable devices remain overwhelmingly import-dependent.
• Regulatory maturity: Low-to-medium by international comparison, and — distinctively for this site's country coverage — largely undocumented in English-language secondary sources. IMED/IFDA's classification logic tracks the international GHTF four-class model in broad strokes, but published, current, English-language detail on review procedures, fees, and timelines is scarce; this scarcity is itself part of why this page treats sourced facts and flagged gaps as equally important content.

Regulatory Authority and Legal Framework

• Competent authority: Islamic Republic of Iran Food and Drug Administration (IFDA), operating under the Ministry of Health and Medical Education (MOHME).
• Operating unit: The Medical Equipment Directorate at MOHME/IFDA is responsible for supervising medical device imports and registration; industry and public materials commonly refer to this function as IMED, the Department of Medical Equipment, or the Medical Equipment Office. A Medical Device Board (MDB) is reported to review registration applications for safety and performance and to maintain the exclusion list that determines whether a device needs full technical review rather than the general-licence route.
• Legal device definition: IFDA's own definition of a "medical device," as reported in the source material for this page, covers any product, device, equipment, tool, accessory, machine, implant, material, reagent, laboratory calibrator, or software intended by the manufacturer for use (alone or combined) for: (1) diagnosis, monitoring, prevention, or treatment of disease; (2) life support or sustaining; (3) control or contraception; (4) sterilisation, disinfection, or cleaning of equipment, environments, or medical waste; (5) providing medical information via laboratory methods on human samples; (6) diagnosis, monitoring, treatment, relief, compensation, or correction of injury, disability, or physiological/anatomical processes; (7) study, evaluation, replacement, or correction of physiology or anatomy; or (8) regulation of medical equipment and supplies.
• Governing instruments: 【待核验 — the specific act, decree, or ministerial regulation establishing IFDA's medical-device registration authority was not identified in sources available this round. Published English-language secondary sources describe IFDA/MOHME's practice and the Medical Device Board's role, but do not cite a specific statute number; a local Iranian regulatory agent should confirm the exact legal basis before a submission-critical filing.】
• Official portals: https://fda.gov.ir and https://imed.ir are understood to be the relevant official web presences; both were unreachable from the network used to research this page (connection refused / reset), consistent with the previous verification round on 2026-07-01. A local agent with in-country network access should be used to confirm current portal content, forms, and any online submission system before filing.

Market-Entry Logic

Iran medical device entry cannot be reduced to a product-registration question alone. Because so much of the practical pathway runs through a local agent operating under sanctions-constrained banking and logistics conditions, a realistic entry plan has to weight regulatory, commercial, and compliance factors together from the outset.

For a foreign manufacturer, this means separating four questions that a single distributor conversation tends to blur together: who can legally register and hold the IRC; who can clear customs and manage currency allocation shipment by shipment; who has genuine hospital and specialty-channel access; and who can sustain installation, training, and after-sales service for as long as the product remains on the Iranian market.

Local Market and Player Map

This is a due-diligence map, not a ranking. Because more than 100 Iranian companies were reported (as of 2020) to represent international suppliers, and because none of the major multinational device brands maintains a direct local entity, screening the candidate local partner is arguably the single highest-leverage step in an Iran entry project:

• Local representative / importer: verify real IRC registration history, import-licensing standing, and hospital-channel evidence — not just a claimed relationship.
• Specialty distributor: for high-value consumables, implants, IVDs, and imaging equipment, prioritize companies with department-level relationships, clinical training capability, and service infrastructure.
• Domestic manufacturing or assembly partner: for basic consumables and price-sensitive categories, assess under-license, assembly, contract-manufacturing, or technology-transfer models against the reality that low-cost local substitutes already exist for many product categories.
• Public procurement and hospital networks: public and university hospitals weight price, availability, and continuity of supply heavily, given the visible history of foreign-exchange and logistics interruptions; private and specialty-center channels respond faster to brand and service but still require independent verification of payment and import routes.

Development Trends

• Self-sufficiency policy continues to push local manufacturing, particularly for consumables and mid-complexity equipment, driven partly by foreign-currency conservation goals — a structural pressure that predates and outlasts any single sanctions episode.
• European-origin products retain a strong market-preference position, per the 2020 industry briefing, with buyers reported to trust European (and by extension CE-marked) devices over both local production and non-European imports — a commercial reality distinct from, and not proof of, any specific formal regulatory precondition (see Element 8).
• Payment and logistics friction is a persistent, structural feature of the market, not a one-time event — the 2020 briefing describes foreign exchange and import regulation as a standing challenge for European exporters, and payment-channel workarounds such as the EU-Iran INSTEX mechanism (its first recorded transaction, in March 2020, was a German medical device sale) illustrate how much of Iran market access has historically depended on payment infrastructure rather than registration status alone. 【待核验 — INSTEX's operational status by 2026 was not confirmed this round; treat any reference to it as historical context from the 2020 source rather than a current payment channel.】
• Registration and import records are becoming more system-dependent in general regulatory practice across the region, though the extent of this specifically for Iran's IRC and import-permit systems could not be independently verified this round.
• Compliance screening has become a precondition for serious market entry, not a parallel workstream — a project that can register a product but cannot legally bank, ship, and get paid for it is not a viable business, independent of how favorable the underlying registration terms are.

Element 1 — Device Classification and Pathway Branching

Iran's classification model follows the international GHTF (Global Harmonization Task Force) four-class risk framework, the same underlying model referenced by many jurisdictions worldwide, including the EU's legacy MDD-era system. Confirm current classification through IMED or a local regulatory agent before committing to a dossier, since Iran's own current classification guidance was not directly reachable this round.

Pathway Branching — Registration Route by Product Category

Branching logic in practice: the exclusion list, not the Class A–D letter by itself, appears to be the operative fork between the faster general-licence route and full MDB technical review — this is a meaningfully different branching logic from ASEAN- or EU-style class-based review triggers, and it is exactly the kind of detail a manufacturer should have a local agent confirm against IMED's current exclusion list before assuming a device will qualify for the lighter route. 【待核验 — current exclusion-list contents and any post-2020 changes to this branching logic were not identified in sources available this round.】

Element 2 — License-Holder Logic: The Local Representative Is a Decision-Grade Choice

This is the fact that should anchor every Iran market-entry conversation: no verified source located this round shows a foreign manufacturer registering a device or holding an IRC directly — every credible account of the market, from the 2020 industry briefing to the existing due-diligence practice reflected in this page's prior version, describes international suppliers reaching Iran exclusively through a locally established Iranian company acting as authorised representative, importer, or both.

• No direct legal presence among major brands: per the 2020 industry briefing, none of the leading multinational medical device manufacturers — including large European names such as Philips, Siemens, Medtronic, and Smith & Nephew — maintains its own office inside Iran. All products move through local agents or distributors, who also typically handle after-sales service on the manufacturer's behalf.
• Scale of the agent market: more than 100 Iranian companies were reported (as of 2020) to be active in this representative/importer role, indicating a reasonably deep — if fragmented — pool of candidate partners rather than a small handful of gatekeepers, which is itself a due-diligence point: breadth of choice increases the importance of verifying real registration and import-licensing capability rather than defaulting to the first available contact.
• What is not verified: whether the local-representative requirement is a hard statutory mandate (comparable to Malaysia's or Saudi Arabia's Authorized Representative regimes) versus a practical market reality driven by banking, logistics, and language barriers that make direct foreign operation impractical. 【待核验 — this page treats "essentially mandatory in practice" as the accurate, sourced characterization, and does not claim a specific statutory citation for a formal legal mandate.】

Structuring Options

• Contract terms matter disproportionately here precisely because there is no verified regulatory floor (such as a mandatory Establishment Licence renewal cycle) governing the agent relationship — registration-file access, transfer rights, termination handling, and renewal responsibility should be defined in the commercial agreement itself, not assumed to follow a standard regulatory pattern, since Iran's own procedural rules on this point could not be confirmed this round.
• Changing agents carries real supply-continuity risk. If the same entity holds both the registration/IRC and the commercial relationship, ending that relationship risks an interruption while any transfer process is completed — and whether IMED operates a defined registration-transfer procedure at all was not confirmed this round. This risk should be assumed and contracted around, not assumed away.

Element 3 — Registration Validity and Review-Timeline Ranges

Why this section is thinner than comparable pages on this site: unlike Malaysia, Thailand, or Saudi Arabia, where multiple independent regulatory-services firms publish cross-checked timeline estimates, Iran's market-entry literature is dominated by trade-compliance and sanctions material rather than procedural regulatory-affairs detail — a direct consequence of the country's limited coverage by Western regulatory consultancies. Where this page cannot honestly state a number, it says so rather than estimating one.

Element 4 — Local Representative In-Country Obligations

Holding a registration or import permit is not a one-time event. Based on the market structure described in available sources — a local agent handling both regulatory standing and after-sales service on the manufacturer's behalf — the following obligations are reasonably attributed to the local representative, with confirmation status noted honestly where a specific procedural detail was not independently verified.

Practically, the absence of a confirmed, codified obligations list (compared with, for example, Malaysia's GDPMD/vigilance-timeline framework) is itself useful information: a manufacturer entering Iran should not assume a standard, internationally comparable post-market compliance regime exists in codified form, and should instead negotiate specific service-level commitments — vigilance handling, recall cooperation, and renewal management — directly into the local agent contract rather than relying on an assumed regulatory floor.

Element 5 — Fee Model

No official, current, publicly verifiable fee schedule for Iranian medical device registration was located in the sources available this round — neither IMED's own portal (unreachable from the research network used) nor any independent regulatory-services summary covering Iran specifically. This section states the fee structure implied by the regulatory model described above, with every specific amount flagged as unverified.

Why fees cannot be honestly estimated here: Iran's currency has experienced substantial volatility over the period since the 2020 source used for this page, which means even a historical Rial figure, if one existed in the source material, would not translate into a stable or meaningful USD-equivalent cost today. Rather than convert a stale figure into a misleadingly precise-looking dollar estimate, this page states plainly that a current fee schedule must come directly from IMED or a local agent at the time of filing.

Element 6 — Registration Forms

A structural note worth stating plainly: Iran's registration architecture, as sourced, resembles a binary fork (general licence versus full MDB review triggered by an exclusion list) rather than the four-parallel-track class-based systems seen in ASEAN markets or the Notified-Body conformity-assessment model used in the EU. This is a materially different, and materially less documented, system — treat any comparison to a better-documented market's procedural detail as directional only.

Element 7 — Special Requirements

Persian-Language Labeling and IFU

Consistent with the general pattern across the Middle East and North Africa region, Persian (Farsi) labeling and instructions-for-use content are expected for devices reaching the Iranian market, coordinated through the local representative. 【待核验 — Iran's specific official labeling-content regulation (required data fields, dual-language allowances, packaging-mockup approval process) was not independently located or verified this round; confirm current requirements directly with IMED or the local agent before finalizing artwork.】

Import Permits and Batch Release for High-Risk Equipment

High-risk medical equipment is reported to require batch release — each import consignment cleared individually rather than under a single blanket authorisation tied to the device registration. This means import planning for high-risk equipment needs to budget for a recurring, per-shipment clearance step, not just the one-time registration process, and that supply continuity depends on the local agent's ongoing ability to clear each batch, not only on the underlying registration remaining valid.

Currency Allocation for Imports — A Practical, Not Merely Regulatory, Constraint

Foreign-exchange access for importers has been described in available sources as a standing, structural challenge, distinct from and layered on top of product registration status. Iran's broader system of prioritizing foreign-currency allocation for categories of goods it treats as essential — historically including medicine and medical equipment — has been referenced in general public reporting on Iran's trade administration, but this page could not independently verify the current mechanism, eligibility criteria, or processing timeline for medical-device-specific currency allocation this round. 【待核验 — treat any specific claim about current currency-allocation platforms, preferential rates, or eligibility categories as requiring direct confirmation from a local agent or the Central Bank of Iran's current published rules; do not rely on historical descriptions as current policy.】 Practically, this means a manufacturer's local agent needs demonstrated, current experience securing import currency for medical shipments — not just registration experience — as part of partner due diligence.

Used and Refurbished Equipment

Import of used or refurbished medical equipment is reported to be prohibited by default, with the Medical Device Board able to grant special permission as an exception. This is relevant for donated equipment, demonstration units, and reconditioned-equipment business models specifically.

Trade-Restriction Context — A Brief, Neutral Note

Medical devices and medicine are generally treated as favored categories under international sanctions frameworks affecting Iran: general-licence and humanitarian-exemption mechanisms exist under both US and EU sanctions regimes that are specifically structured to permit trade in medicine and medical devices, subject to conditions and exclusion lists that vary by regime and change over time. This page does not provide export-control or sanctions guidance, does not describe how to structure a transaction to fit within any exemption, and does not track current exclusion-list contents, licensing conditions, or enforcement posture. Any manufacturer or distributor considering Iran must obtain independent export-control and sanctions counsel and confirm current requirements directly with the relevant authorities (e.g., the US Treasury's Office of Foreign Assets Control, the EU's sanctions framework, and equivalent authorities in the manufacturer's home jurisdiction) before proceeding with any transaction. Payment and banking-channel friction, separate from whether a transaction is legally permitted, has also been a persistent, independently reported practical constraint on Iran market access — a compliant transaction can still be operationally difficult to execute.

Element 8 — Reference-Country Leverage: CE, FDA, and What Could Not Be Confirmed

The task of describing how Iran treats foreign reference-market approvals runs directly into this page's central honesty constraint: available sources demonstrate a strong commercial and market-preference pattern favoring CE-marked, European-origin devices, but do not provide a directly verified statement of IMED's formal regulatory treatment of CE, FDA, or other reference-market approvals as a registration precondition.

What the Available Evidence Shows

Practical Recommendation

Given this evidence gap, a manufacturer should plan to bring a complete CE or FDA (or other major-market) technical file and approval evidence to the Iran filing regardless of whether it is formally mandatory, because: (1) it is very likely to accelerate the practical review given the Medical Device Board's apparent reliance pattern, even if not a strict legal precondition; (2) it materially strengthens the local agent's ability to market the product against the documented buyer preference for CE-marked devices; and (3) it is the standard practice implied by every credible account of how international brands actually reach the Iranian market today. Do not, however, assume this substitutes for Iranian registration and IRC issuance — no source reviewed this round suggests foreign approvals waive the local process, only that they plausibly ease it.

IVD-Specific Requirements

• IVDs are reported to represent roughly 33,000 of the approximately 280,000 medical device types available in Iran, of which around 89% are imported — making IVDs one of the most import-dependent categories in the market.
• IVDs follow the same GHTF-aligned Class A–D structure and the same general-licence/exclusion-list branching logic described in Element 1 and Element 6; no IVD-specific classification guidance document was independently located this round. 【待核验】
• Cold-chain, reagent-supply continuity, and calibration/QC support are practical concerns specific to IVD and laboratory-system market entry in Iran, given the same currency-allocation and payment-channel constraints described under Element 7 — a registered IVD product still depends on a functioning, continuous import/payment pipeline for reagents and consumables, not just a one-time device approval.
• 【待核验 — whether Iran imposes mandatory local testing or validation requirements for specific high-risk IVD categories (e.g., infectious-disease screening assays) was not confirmed in sources available this round.】

SaMD and Digital Health Note

No source reviewed for this page addresses Software as a Medical Device (SaMD) classification, registration treatment, or digital-health-specific requirements in Iran. 【待核验 — SaMD/digital-health regulatory treatment in Iran was not identified in any source available this round; a manufacturer with a software-only or connected-device product should treat this as an open question requiring direct confirmation from IMED or a local regulatory agent, not assume treatment analogous to hardware devices or to any other country's SaMD framework.】 Given how limited even hardware-device procedural documentation is for Iran, SaMD-specific guidance is plausibly even less mature or less published — a reasonable planning assumption, but not a confirmed fact.

Registration Dossier Requirements

Post-Market Surveillance, Adverse Event Reporting, and Recalls

No specific Iranian vigilance-reporting timeline, recall-classification framework, or post-market surveillance procedure was independently confirmed in sources available this round. 【待核验 — this entire section should be treated as an open question for direct confirmation with IMED or the local agent, not as an established, codified regime comparable to the ASEAN or GCC pages on this site.】 What can be stated with reasonable confidence from the market-structure evidence:

• After-sales service, including presumably complaint handling, is reported to run through the same local agent/distributor that manages registration and import — there is no evidence of a separate manufacturer-run vigilance channel operating independently of the local agent.
• Given the reported batch-release control on high-risk equipment imports, ongoing supply (and by extension, any recall or corrective-action logistics) is dependent on the local agent's continued ability to clear shipments, not solely on the underlying registration remaining valid.
• A manufacturer should negotiate specific complaint-handling, adverse-event-escalation, and recall-cooperation commitments directly into the local agent contract, given the absence of a confirmed default regulatory framework to fall back on.

Import and Customs Requirements

• Registration/IRC as a precondition: import is understood to require an underlying, valid registration or import permit held by the local representative — direct-to-market import without local registration standing is not evidenced as a viable route in any source reviewed.
• Batch release for high-risk equipment: each import consignment of high-risk equipment reportedly requires individual clearance, layered on top of the device-level registration — see Element 7.
• Currency allocation: foreign-exchange access for import payment is a recurring, structurally significant constraint independent of registration status — see Element 7. Do not assume that a completed registration alone guarantees the ability to pay for and import the next shipment.
• Used/refurbished equipment: prohibited by default; Medical Device Board special permission is the only documented exception.
• Persian labeling at the point of entry: expected as a general regional pattern; exact official content requirements not independently verified this round.

Market Access Channels

Registration and import clearance are the compliance entry point, not the commercial one.

• Public and university hospitals: the largest-volume channel by structure, prioritizing price, product availability, and supply continuity — buyers are reported to weight these factors heavily given the market's documented history of foreign-exchange and logistics interruptions.
• Private hospitals and specialty centers: respond faster to brand reputation, physician relationships, and service quality; also the more likely entry point for premium equipment and novel technologies ahead of broader public-channel adoption.
• Medical-tourism-linked facilities: given more than 600,000 reported medical travelers in 2019 (pre-dating any more recent shift), specialty centers serving ophthalmology, cosmetic/orthopaedic surgery, cardiac/thoracic care, and dermatology represent a distinct demand channel for premium and diagnostic technologies, concentrated in facilities positioned for international patients.
• Local agent/distributor network: more than 100 companies were reported active in the registration/import/distribution role as of 2020 — a reasonably broad candidate pool, making partner due diligence (not partner scarcity) the operative constraint.
• Domestic manufacturing/localisation partnerships: relevant for basic consumables and price-sensitive categories facing local-substitute competition; under-license, assembly, or technology-transfer models are the reported structures for foreign manufacturers seeking a localized cost position.

Market Entry Strategy and Key Risks

Recommended approach:

• Treat compliance screening as the first gate, not a parallel workstream. Confirm the transaction — product, counterparty, bank, logistics, payment route — is clear from an export-control/sanctions standpoint with qualified independent counsel before committing commercial or regulatory resources; see Element 7.
• Select the local representative on verified registration and import-licensing history, not on quoted speed or price alone. With 100+ reported candidate agents, breadth of choice raises rather than lowers the due-diligence bar.
• Bring complete CE/FDA (or other major-market) evidence regardless of formal-mandate uncertainty. Per Element 8, this plausibly eases review and directly supports the documented buyer preference for CE-marked, European-origin devices.
• Budget for batch-by-batch import clearance and currency allocation as ongoing operational work, not one-time setup tasks — this is distinct from, and continues well after, initial registration.
• Negotiate vigilance, recall-cooperation, and renewal-management commitments explicitly into the local agent contract, since no confirmed codified regulatory floor governs these obligations the way it does in more thoroughly documented markets.

Key risks:

• Certificate/registration lock-in with a combined agent-distributor. If the same entity holds registration/import standing and the commercial relationship, ending that relationship risks a supply interruption — and whether IMED operates a defined transfer procedure was not confirmed this round.
• Treating "medical use" as automatic tradability. Favorable general-licence and humanitarian-exemption treatment for medical devices does not eliminate the need to screen the full transaction — counterparty, bank, logistics, and end user — under current export-control and sanctions rules.
• Underestimating currency-allocation and payment friction as a post-registration risk. A successfully registered product can still face supply interruption if the local agent cannot secure import currency or maintain a functioning payment channel — this is a distinct risk from registration validity.
• Relying on informal timeline or fee estimates from a single broker. Given how little of Iran's official procedural detail is independently verifiable, treat any specific number not sourced to this page's citations, or to direct IMED/local-agent confirmation, with real skepticism.
• Assuming ASEAN- or GCC-style codified post-market obligations exist by default. Iran's vigilance, recall, and renewal framework is not documented to the same depth as those markets in any source reviewed — contract for these commitments explicitly rather than assuming a regulatory backstop.

Practical tips:

• Confirm current classification, exclusion-list status, fees, and timelines directly with IMED or a local agent with working access to https://imed.ir and https://fda.gov.ir — both were unreachable from the network used to research this page.
• Obtain independent, current export-control and sanctions counsel before any commercial commitment — this page is market-entry research material only, not sanctions or legal advice.
• Ask any candidate local agent for verifiable, recent examples of both successful registration/IRC issuance and successful import currency allocation — registration capability and import-execution capability are not the same thing, and a partner may credibly have only one.

Frequently Asked Questions

Who regulates medical devices in Iran?

The Islamic Republic of Iran Food and Drug Administration (IFDA), under the Ministry of Health and Medical Education (MOHME), is Iran's national regulator. Devices are handled through IFDA's Medical Equipment Directorate, commonly called IMED in industry usage, with application review reported to run through a Medical Device Board (MDB).

Does Iran require a mandatory local representative or importer?

In practice, yes — every credible source reviewed for this page, including a 2020 industry briefing and this site's prior research, describes international suppliers reaching Iran exclusively through a locally established Iranian company acting as registration holder, importer, or both. No source located this round documents a foreign manufacturer registering directly. Whether this is a strict statutory mandate or a practical market reality was not independently confirmed — see Element 2.

How long is an Iranian medical device registration valid?

Four years, per a November 2020 EU-funded industry briefing (SPECTARIS/Sanctions Helpdesk for Business) — not independently re-confirmed against a live IMED source this round. Confirm directly with IMED or a local agent before a submission-critical filing.

How long does Iranian medical device registration take?

This page could not locate a verifiable official or cross-checked secondary timeline figure this round — see Element 3. Given how thinly documented Iran's regulatory-affairs procedural detail is in available English-language sources, treat any specific timeline quoted informally as unconfirmed until an IMED or local-agent source verifies it directly.

Does an existing CE or FDA approval help with Iranian registration?

Available evidence shows a strong market preference for CE-marked, European-origin devices and a market pattern in which international brands reaching Iran already hold established reference-market approvals — but this page could not independently confirm whether CE or FDA approval is a formal regulatory precondition for IMED registration, as opposed to a strong practical and commercial advantage. See Element 8. Bringing complete reference-market evidence is recommended regardless of the answer to that open question.

Do international sanctions block medical device exports to Iran?

Medical devices and medicine are generally treated as favored categories under general-licence and humanitarian-exemption provisions in both US and EU sanctions frameworks affecting Iran, but the specific conditions, exclusion lists, and licensing requirements vary and change over time. This page does not provide export-control or sanctions guidance. Any manufacturer or distributor must obtain independent, current export-control and sanctions counsel and confirm requirements directly with the relevant authorities before proceeding — see Element 7.

Are IVDs and SaMD registered differently from general medical devices in Iran?

IVDs follow the same GHTF-aligned Class A–D structure described in Element 1, and represent one of the most import-dependent categories in the market (roughly 89% imported, per the 2020 industry briefing). No IVD-specific classification guidance was independently located this round. SaMD/digital-health regulatory treatment in Iran was not addressed in any source reviewed for this page — treat this as an open question requiring direct IMED confirmation, not an assumption of hardware-equivalent treatment. See the IVD and SaMD sections above.

Why is this page shorter on confirmed procedural detail than other country pages on this site?

By design, not oversight. Iran is genuinely thinly covered by Western regulatory consultancies, IMED's own portal was unreachable during this page's research, and general web search returned no usable results this round. Rather than filling that gap with invented fees, timelines, or procedural claims, this page states what a verified EU-funded industry briefing and official sanctions guidance actually document, and flags the rest — clearly and repeatedly — as requiring direct confirmation from IMED or a local Iranian regulatory agent.

Official Sources and Verification Dates

• Islamic Republic of Iran Food and Drug Administration — official portal: https://fda.gov.ir (attempted 2026-08-17; connection reset, unreachable from the research network used)
• Medical Equipment Directorate / IMED — official portal: https://imed.ir (attempted 2026-08-17; connection refused, unreachable from the research network used, consistent with the prior verification attempt on 2026-07-01)
• SPECTARIS / European Sanctions Helpdesk for Business, The Medical Devices Industry in Iran (November 2020) — primary sourced document for classification examples, GHTF-model risk classes, registration-licence 4-year validity, general-licence/exclusion-list structure, Medical Device Board role, batch-release requirement for high-risk equipment, used/refurbished equipment prohibition, market-size and import-dependence figures, agent/distributor market structure, medical-tourism figures, and INSTEX historical payment-mechanism context: https://www.spectaris.de/fileadmin/Infothek/Verband/Au%C3%9Fenwirtschaft/Iran/2020.11._The_Medical_Devices_Industry_in_Iran_0.pdf (accessed 2026-08-17; document dated November 2020 — treat all figures as historical unless independently reconfirmed)
• US Treasury Office of Foreign Assets Control (OFAC), FAQ 482, Iran-related medical device and medicine authorisations: https://ofac.treasury.gov/faqs/482 (attempted 2026-08-17; request timed out on this round — cited per this site's prior verified reference as of 2026-07-01; reconfirm directly before relying on it for a compliance decision)
• Verification date: 2026-08-17. Direct fetch of IMED's and IFDA's own portals failed on this round from the research network used; this page relies on the verified secondary industry briefing above plus general, non-Iran-specific export-control framework knowledge for the brief compliance note in Element 7, and flags every unconfirmed figure explicitly rather than presenting it as sourced.

Items flagged for further verification (【待核验】)

• The precise statute, decree, or ministerial regulation establishing IFDA's medical-device registration authority.
• Current review-timeline ranges for both the general-licence and full Medical Device Board review routes.
• Current official fee schedule for registration, full technical review, import permits, and renewals.
• Whether the 4-year registration validity figure (sourced to a 2020 industry briefing) remains current.
• Whether local representation is a strict statutory mandate or a practical market reality without a specific direct-registration prohibition on record.
• Current exclusion-list contents determining the general-licence versus full-MDB-review fork.
• Whether IMED imposes CE, FDA, or other reference-market approval as a formal registration precondition, versus a strong commercial/practical advantage only.
• Current official Persian-labeling content requirements (required fields, packaging-mockup approval process, dual-language allowances).
• Current currency-allocation mechanism, eligibility criteria, and processing timeline for medical-device imports.
• Whether high-risk IVD categories carry mandatory local testing or validation requirements.
• SaMD/digital-health-specific classification and registration treatment.
• Codified vigilance-reporting timelines, recall-classification framework, and post-market surveillance procedure, if any exist in official form.
• Current operational status of the INSTEX payment mechanism referenced in the 2020 source.
• Current content and structure of the IMED (imed.ir) and IFDA (fda.gov.ir) official portals, unreachable during this research round.

Updated 2026-08-17. This page is market-entry research material only — it does not constitute legal, sanctions, export-control, registration-filing, or customs-clearance advice. Given the extent of flagged, unverified detail above, a local Iranian regulatory agent and independent export-control/sanctions counsel should be engaged before any commercial or regulatory commitment.